Pfizer, Inc. (PFE)
NYSE • Healthcare
August 18, 2026 at 20:00 UTC
About Pfizer, Inc.
Pfizer Inc. develops, makes, and sells prescription medicines and vaccines worldwide. Listed on the NYSE as PFE, the company operates in the pharmaceutical business and generated $62.6 billion of revenue in FY2025. Its portfolio spans branded therapies, biosimilars, hospital injectables, and vaccines used across a wide range of treatment and prevention settings.
Analyst Ratings
Fundamentals & Financials
TTM is calculated as the sum of the four most recently completed quarters. This is a standard approach when monthly or real-time data is not available.
Income Statement
Balance Sheet
Financial Highlights
Dividends History
Split History
Earnings Calendar
Technical Indicators
Pfizer, Inc.'s Technical Indicators Summary
PFE shows a strong bullish bias driven by broad moving-average support and positive momentum: the price sits above short, medium and long-term averages, MACD and momentum are positive, and CCI confirms buying pressure while RSI is high. Trend strength is robust with ADX above 30, volume on-balance is constructive, and volatility remains contained with ATR near 2% of price. Classic pivot levels reinforce support just below current levels, aligning with the overall bullish signals. Technical takeaway: Strong Buy.
| Indicator | Value |
|---|---|
RSI (14) | 68.83 |
Stochastic %K (14, 3, 3) | 88.94 |
CCI (20) | 121.07 |
WPR (14) | -5.26 |
Momentum (10) | 1.84 |
MFI | 75.96 |
MACD Level (12, 26) | 0.57 |
Bollinger Bands | $23.97 - $27.66 |
ATR (14) | $0.55 (2.02%) |
ADX (14) | 31.66 |
OBV | 411,960,479 |
Classic Pivot Point | $26.81 |
Fibonacci Pivot Point | $26.81 |
Exponential Moving Averages | $25.62 - $26.56(5 indicators) |
Simple Moving Averages | $25.22 - $26.65(5 indicators) |
Get premium market insights delivered directly to your inbox.
Today's Snapshot
By the close, PFE held onto a small 1.41% gain versus yesterday. End-of-day, the peer group was modestly in the green at 1.59%, providing a small boost to sentiment. EMA validates PFE Lyme vaccine filing, marking a key regulatory milestone.
Trading Volume
Below 10d avg (38.3M)
33.8M
vs S&P 500 Today
Outperforming Market
+2.01%
52-Week Position
Upper range
71%
Updated: August 18, 2026 at 20:38 UTC
Quote Summary
PFE Headlines
Pfizer lifts 2026 outlook amid Covid revenue drop
August 8, 2026
Pfizer lifts 2026 outlook after Q2 revenue rise
August 4, 2026
Pfizer, Innovent sign $10.5B cancer drug pact
May 29, 2026
Ghana rejects US health data deal
May 2, 2026